Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jiang Bai gastritis tablet (Jiangbai Weiyan Pian) is a Traditional Chinese Medicine (TCM) formulation developed by Hangzhou Zhongmei Huadong Pharmaceutical for the treatment of chronic non-atrophic gastritis. It is specifically indicated for patients presenting with epigastric pain and cold coagulation syndrome of stagnation of Qi. The formulation typically includes botanical extracts such as Lignum Dalbergiae Odoriferae (Jiang Xiang) and Rhizoma Atractylodis Macrocephalae (Bai Zhu), which are traditionally used to regulate Qi, resolve blood stasis, and tonify the spleen. The drug has been evaluated in Phase II clinical trials to assess its efficacy and safety in improving gastric symptoms and mucosal health in patients with chronic gastritis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Jiang Bai gastritis tablet.